Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation (Q38047084)

27 August 2017

Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation (English)

1 reference

27 August 2017

0 references

Paul D Griffiths

1

1 reference

27 August 2017

24 September 2012

1 reference

Lancet Infectious Diseases

27 August 2017

1 reference

27 August 2017

12

1 reference

27 August 2017

790-798

1 reference

27 August 2017

10

1 reference

Isolation of Intranuclear Inclusion Producing Agents from Infants with Illnesses Resembling Cytomegalic Inclusion Disease

27 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

INFECTIOUS PULMONARY DISEASE IN PATIENTS RECEIVING IMMUNOSUPPRESSIVE THERAPY FOR ORGAN TRANSPLANTATION

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. II.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Human cytomegalovirus tropism for endothelial/epithelial cells: scientific background and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

The dynamics of human cytomegalovirus replication in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Human Cytomegalovirus (HCMV) Replication Dynamics in HCMV‐Naive and ‐Experienced Immunocompromised Hosts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Congenital cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Acquisition of human cytomegalovirus infection in infants via breast milk: natural immunization or cause for concern?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Young children as a probable source of maternal and congenital cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus Infection in a Day-Care Center

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Influence of sexual activity on cytomegalovirus seroprevalence in the United States, 1988-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

A prospective study of primary cytomegalovirus infection in pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Maternal immunity and prevention of congenital cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Review of cytomegalovirus shedding in bodily fluids and relevance to congenital cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Salivary shedding of Epstein-Barr virus and cytomegalovirus in people infected or not by human immunodeficiency virus 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Washing our hands of the congenital cytomegalovirus disease epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Congenital cytomegalovirus (CMV) epidemiology and awareness

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

CMV in critically ill patients: pathogen or bystander?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus and human immunosenescence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Role of cytomegalovirus in the T cell changes seen in elderly individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Amyloid: little proteins, big clues.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Interrelationships among Quantity of Human Cytomegalovirus (HCMV) DNA in Blood, Donor‐Recipient Serostatus, and Administration of Methylprednisolone as Risk Factors for HCMV Disease following Liver Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Congenital cytomegalovirus: association between dried blood spot viral load and hearing loss

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Infection with cytomegalovirus but not herpes simplex virus induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination--an impact of immunosenescence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus sero positivity dramatically alters the maternal CD8+ T cell repertoire and leads to the accumulation of highly differentiated memory cells during human pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Encouraging prospects for immunisation against primary cytomegalovirus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Incidence of cytomegalovirus infection among the general population and pregnant women in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Women's knowledge of congenital cytomegalovirus: results from the 2005 HealthStyles survey.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Genetic content of wild-type human cytomegalovirus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

T cells and viral persistence: lessons from diverse infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Update on the current status of cytomegalovirus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Vaccine prevention of maternal cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus seroepidemiology in an urban community of São Paulo, Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Modelling immunization strategies with cytomegalovirus vaccine candidates.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Public health and laboratory considerations regarding newborn screening for congenital cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Neonatal cytomegalovirus blood load and risk of sequelae in symptomatic and asymptomatic congenitally infected newborns.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Cytomegalovirus blood viral load and hearing loss in young children with congenital infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital CMV infection involving the central nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Newborn Screening for Severe Combined Immunodeficiency; The Wisconsin Experience (2008–2011)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Impact of diagnostic and confirmatory tests and prenatal counseling on the rate of pregnancy termination among women with positive cytomegalovirus immunoglobulin M antibody titers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Improved prenatal diagnosis of congenital human cytomegalovirus infection by a modified nested polymerase chain reaction.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Passive Immunization during Pregnancy for Congenital Cytomegalovirus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970197-4

7 January 2021

10.1016/S1473-3099(12)70197-4

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

23017365